News Sanofi

Equities

Market Closed - Euronext Paris Other stock markets 11:38:59 2024-04-24 am EDT			Pre-market 01:36:41 am
87.7 ^EUR	-1.29%		86.99	-0.81%

07:32am	Sanofi Q1 profit slips on generic competition, forex effects	RE
06:16am	EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	DJ

Sanofi Q1 profit slips on generic competition, forex effects	01:32am	RE
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance	01:30am	GL
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	12:16am	DJ
AusBiotech announces incoming CEO	Apr. 24	AQ
Sanofi - Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 24	AQ
SANOFI : Bernstein remains its Buy rating	Apr. 24	ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff	Apr. 24	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 23	MT
Sector Update: Health Care	Apr. 23	MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business	Apr. 23	MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News	Apr. 23	RE
CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5	Apr. 23	CF
CAC40: closes in on 8,100, well supported by W-Street	Apr. 23	CF
CAC40: up slightly after encouraging PMI figures	Apr. 23	CF
Sanofi: positive phase III data in IPT	Apr. 23	CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia	Apr. 23	MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial	Apr. 23	DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims	Apr. 23	MT
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 23	GL

No results for this search

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO